Program
RGT001-075
A development code.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2, led by Regor Pharmaceuticals.
Furthest: phase 2, since Feb 24, 20223 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regor Pharmaceuticals | 30 open or running | phase 2since Feb 24, 2022 | Feb 24, 2022 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 24, 2022First study: phase 2 study in Diabetes Mellitus, Type 2First studyNCT05297045 · 17 enrolled · United States
- Feb 1, 2024Phase 2 study in ObesityNCT06277934 · 73 enrolled · United States
- Feb 14, 2025Phase 2 study in ObesityNCT06867718 · 267 enrolled · United States
TargetBeta
GLP1R →read by rule
“RGT001-075 is a small molecule GLP-1 agonist”study text, by rule · the study
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| zenagamtide | Novo Nordisk | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06867718Obesity · United States | 2 | Completed | Nov 6, 2025 | 267 |
| NCT06277934Obesity · United States | 2 | Completed | Aug 13, 2024 | 73 |
| NCT05297045Diabetes Mellitus, Type 2 · United States | 2 | Terminated | May 30, 2023 | 17 |
How it is read
Names in the registry
- “RGT001-075”, 3 entries
Codes read as this program: RGT001075.
Conditions, from the studies’ own filings
- Obesity, 2 studies
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.